Lv11
80 积分 2025-03-06 加入
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
3分钟前
待确认
Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans
23天前
已完结
P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape
1个月前
已关闭
388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study
3个月前
已关闭
Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure
4个月前
已关闭
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
5个月前
已完结
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines
6个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
10个月前
已完结
Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial
1年前
已完结
Targeted therapy for pediatric glioma: RAF(t)ing in the molecular era
1年前
已完结
皖公网安备34019202002308
